BioCentury | May 16, 2016
Finance

Global ambitions

European biotechs not only missed out on the extended bull market that allowed U.S. biotechs to fill their coffers, but also on what could have been an arbitrage opportunity for U.S. investors who found domestic...
BioCentury | Sep 2, 2013
Finance

Reproductive reunion

Reproductive reunion Investors in ObsEva S.A. , the latest spinout from the Merck Serono unit of Merck KGaA (Xetra:MRK), see the newco as an opportunity to reunite with management that previously found success in the reproductive...
BC Week In Review | Jul 1, 2013
Clinical News

Fibristal ulipristal acetate regulatory update

Actavis said Health Canada approved Fibristal ulipristal acetate to treat moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age who are eligible for surgery. The company plans to launch...
BioCentury | Feb 11, 2013
Strategy

Serono's starter kit

In the midst of a major restructuring, Merck KGaA has found a way to preserve access to key assets and skill sets even as the company makes cutbacks aimed at improving its fiscal health. Merck...
BioCentury | Dec 17, 2012
Finance

Sinfully good

Sofinnova Partners has made good money in three areas it says are considered "cardinal sins" among LPs these days: venture, life sciences and Europe. It's now unveiled its first fund with a focus on all...
BioCentury | Apr 2, 2012
Finance

Doubling down

Biotech investors lifted valuations across the board last quarter and made a handful of big bets that were driven by potential acquisitions, lawsuit settlements, strong earnings and positive clinical and regulatory news. At least one...
BC Week In Review | Mar 19, 2012
Clinical News

Esmya ulipristal acetate: Phase III started

Watson began a double-blind, U.S. Phase III trial to compare 10 mg Esmya plus iron vs. placebo plus iron in about 300 women with anemia associated with uterine fibroids who are planning a hysterectomy or...
BioCentury | Mar 19, 2012
Strategy

Remaking Merck Serono

Five years after spending $13.2 billion to acquire Serono S.A. as a growth platform, Merck KGaA finds itself with much higher pharmaceutical sales than it could have achieved on its own, but no obvious way...
BC Week In Review | Mar 5, 2012
Clinical News

Esmya ulipristal acetate regulatory update

The European Commission approved an MAA for Esmya ulipristal acetate from PregLem S.A. to treat moderate to severe uterine fibroids in women of reproductive age. PregLem is part of Gedeon Richter. Richter gained the selective...
BC Extra | Feb 28, 2012
Company News

EC approves Esmya

The European Commission approved an MAA from PregLem S.A. for Esmya ulipristal acetate to treat moderate to severe uterine fibroids. PregLem is part of Gedeon Richter Ltd. (Budapest:RICHTER)....
Items per page:
1 - 10 of 44
BioCentury | May 16, 2016
Finance

Global ambitions

European biotechs not only missed out on the extended bull market that allowed U.S. biotechs to fill their coffers, but also on what could have been an arbitrage opportunity for U.S. investors who found domestic...
BioCentury | Sep 2, 2013
Finance

Reproductive reunion

Reproductive reunion Investors in ObsEva S.A. , the latest spinout from the Merck Serono unit of Merck KGaA (Xetra:MRK), see the newco as an opportunity to reunite with management that previously found success in the reproductive...
BC Week In Review | Jul 1, 2013
Clinical News

Fibristal ulipristal acetate regulatory update

Actavis said Health Canada approved Fibristal ulipristal acetate to treat moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age who are eligible for surgery. The company plans to launch...
BioCentury | Feb 11, 2013
Strategy

Serono's starter kit

In the midst of a major restructuring, Merck KGaA has found a way to preserve access to key assets and skill sets even as the company makes cutbacks aimed at improving its fiscal health. Merck...
BioCentury | Dec 17, 2012
Finance

Sinfully good

Sofinnova Partners has made good money in three areas it says are considered "cardinal sins" among LPs these days: venture, life sciences and Europe. It's now unveiled its first fund with a focus on all...
BioCentury | Apr 2, 2012
Finance

Doubling down

Biotech investors lifted valuations across the board last quarter and made a handful of big bets that were driven by potential acquisitions, lawsuit settlements, strong earnings and positive clinical and regulatory news. At least one...
BC Week In Review | Mar 19, 2012
Clinical News

Esmya ulipristal acetate: Phase III started

Watson began a double-blind, U.S. Phase III trial to compare 10 mg Esmya plus iron vs. placebo plus iron in about 300 women with anemia associated with uterine fibroids who are planning a hysterectomy or...
BioCentury | Mar 19, 2012
Strategy

Remaking Merck Serono

Five years after spending $13.2 billion to acquire Serono S.A. as a growth platform, Merck KGaA finds itself with much higher pharmaceutical sales than it could have achieved on its own, but no obvious way...
BC Week In Review | Mar 5, 2012
Clinical News

Esmya ulipristal acetate regulatory update

The European Commission approved an MAA for Esmya ulipristal acetate from PregLem S.A. to treat moderate to severe uterine fibroids in women of reproductive age. PregLem is part of Gedeon Richter. Richter gained the selective...
BC Extra | Feb 28, 2012
Company News

EC approves Esmya

The European Commission approved an MAA from PregLem S.A. for Esmya ulipristal acetate to treat moderate to severe uterine fibroids. PregLem is part of Gedeon Richter Ltd. (Budapest:RICHTER)....
Items per page:
1 - 10 of 44